Infliximab administered as 3-dose induction followed by scheduled maintenance therapy in IBD: comparable clinical outcomes with or without concomitant immunomodulators | Zendy

AI Assistant Blog Pricing

Infliximab administered as 3-dose induction followed by scheduled maintenance therapy in IBD: comparable clinical outcomes with or without concomitant immunomodulators

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.